D L Carlson Investment Group Decreased By $2.44 Million Its Abbvie (ABBV) Position; Cinemark Holdings (CNK) SI Increased By 6.47%

January 14, 2018 - By Clifton Ray

D L Carlson Investment Group Inc decreased Abbvie Inc. (ABBV) stake by 50.77% reported in 2017Q3 SEC filing. D L Carlson Investment Group Inc sold 27,676 shares as Abbvie Inc. (ABBV)’s stock rose 6.17%. The D L Carlson Investment Group Inc holds 26,832 shares with $2.38 million value, down from 54,508 last quarter. Abbvie Inc. now has $160.19B valuation. The stock increased 1.08% or $1.07 during the last trading session, reaching $100.34. About 4.37 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 14, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Cinemark Holdings Incorporated (NYSE:CNK) had an increase of 6.47% in short interest. CNK’s SI was 11.47M shares in January as released by FINRA. Its up 6.47% from 10.78 million shares previously. With 1.47M avg volume, 8 days are for Cinemark Holdings Incorporated (NYSE:CNK)’s short sellers to cover CNK’s short positions. The SI to Cinemark Holdings Incorporated’s float is 10.92%. The stock increased 1.41% or $0.49 during the last trading session, reaching $35.32. About 720,270 shares traded. Cinemark Holdings, Inc. (NYSE:CNK) has risen 15.13% since January 14, 2017 and is uptrending. It has underperformed by 1.57% the S&P500.

Cinemark Holdings, Inc., together with its subsidiaries, engages in the motion picture exhibition business. The company has market cap of $4.11 billion. It operates theatres in the United States, Brazil, Argentina, Chile, Colombia, Peru, Ecuador, Honduras, El Salvador, Nicaragua, Costa Rica, Panama, Guatemala, Bolivia, Curacao, and Paraguay. It has a 16.74 P/E ratio. As of August 10, 2017, the firm operated 529 theatres and 5,926 screens.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.15, from 1.07 in 2017Q2. It fall, as 42 investors sold Cinemark Holdings, Inc. shares while 87 reduced holdings. 37 funds opened positions while 82 raised stakes. 109.53 million shares or 5.25% more from 104.06 million shares in 2017Q2 were reported. Blackrock stated it has 0.02% of its portfolio in Cinemark Holdings, Inc. (NYSE:CNK). World Asset Mgmt Incorporated reported 0.01% of its portfolio in Cinemark Holdings, Inc. (NYSE:CNK). South Street Advsrs Limited Liability holds 0.32% of its portfolio in Cinemark Holdings, Inc. (NYSE:CNK) for 45,080 shares. Hodges Capital Mgmt stated it has 184,722 shares. Bokf Na owns 21,112 shares. 3,454 were accumulated by Tower Ltd Liability Com (Trc). Montecito Bankshares And accumulated 0.09% or 7,500 shares. Highvista Strategies Limited Com reported 11,500 shares. Stifel Finance has invested 0.01% in Cinemark Holdings, Inc. (NYSE:CNK). Bb&T Corporation reported 12,896 shares. Louisiana State Employees Retirement accumulated 28,300 shares or 0.05% of the stock. Advantus Cap Mngmt invested 0.01% of its portfolio in Cinemark Holdings, Inc. (NYSE:CNK). Laurion Management Limited Partnership holds 0% or 5,649 shares in its portfolio. Paloma Prtnrs Mngmt holds 0.01% in Cinemark Holdings, Inc. (NYSE:CNK) or 10,593 shares. Cubist Systematic Strategies Limited reported 38,945 shares.

Among 21 analysts covering Cinemark Holdings (NYSE:CNK), 14 have Buy rating, 2 Sell and 5 Hold. Therefore 67% are positive. Cinemark Holdings had 63 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Cinemark Holdings, Inc. (NYSE:CNK) has “Outperform” rating given on Wednesday, July 26 by Wedbush. The stock of Cinemark Holdings, Inc. (NYSE:CNK) has “Underweight” rating given on Thursday, October 15 by Morgan Stanley. B. Riley & Co downgraded the shares of CNK in report on Wednesday, March 30 to “Neutral” rating. The stock of Cinemark Holdings, Inc. (NYSE:CNK) has “Mkt Perform” rating given on Monday, April 3 by FBR Capital. The stock of Cinemark Holdings, Inc. (NYSE:CNK) has “Buy” rating given on Monday, November 6 by FBR Capital. Wunderlich maintained Cinemark Holdings, Inc. (NYSE:CNK) rating on Thursday, January 14. Wunderlich has “Buy” rating and $40 target. As per Monday, November 14, the company rating was maintained by RBC Capital Markets. The rating was initiated by Benchmark on Thursday, July 23 with “Buy”. Wedbush maintained the stock with “Buy” rating in Monday, January 8 report. Wedbush maintained the stock with “Neutral” rating in Thursday, February 16 report.

Since December 12, 2017, it had 0 insider purchases, and 1 insider sale for $10.92 million activity. Another trade for 299,700 shares valued at $10.92M was sold by MITCHELL LEE ROY.

Since July 31, 2017, it had 0 buys, and 8 insider sales for $45.57 million activity. Another trade for 87,040 shares valued at $8.57M was made by RICHMOND TIMOTHY J. on Monday, December 18. On Monday, July 31 the insider Gosebruch Henry O sold $21,127. 6,699 shares valued at $589,512 were sold by Michael Robert A. on Thursday, September 28. 193,131 shares were sold by GONZALEZ RICHARD A, worth $13.71 million on Monday, August 7. The insider SALEKI-GERHARDT AZITA sold 8,300 shares worth $705,655. On Thursday, December 14 the insider Schumacher Laura J sold $14.07M.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on January, 26. They expect $1.43 earnings per share, up 19.17% or $0.23 from last year’s $1.2 per share. ABBV’s profit will be $2.28 billion for 17.54 P/E if the $1.43 EPS becomes a reality. After $1.41 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 1.42% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>